Sulfonylurea derivative and pharmaceutical composition and application thereof

A technology of derivatives and compounds, applied in the field of isotope derivatives, can solve problems such as listing and no drugs

Inactive Publication Date: 2017-03-22
SHANGHAI DE NOVO PHARMA
View PDF0 Cites 40 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the research on these two targets is still in-depth, but there are no drugs...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sulfonylurea derivative and pharmaceutical composition and application thereof
  • Sulfonylurea derivative and pharmaceutical composition and application thereof
  • Sulfonylurea derivative and pharmaceutical composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0138] Embodiment 1: the synthesis of compound 1.7

[0139]

[0140] Step 1: Synthesis of Compound 1.1

[0141] In a 5L four-neck round bottom flask, add chenodeoxycholic acid (190g, 484mmol), sodium bromide (2.5g, 24mmol), tetrabutylammonium bromide (0.5g, 1.55mmol), methanol (616mL), acetic acid (200 mL), water (49 mL), and ethyl acetate (1.33 L). The reaction solution was stirred at room temperature for 15 minutes until the solution was clear, and cooled to 0°C. Sodium hypochlorite (~5%, 756g, 508mmol) was slowly added dropwise to the reaction system, and the internal temperature was controlled at 1-2°C (exothermic). After the dropwise addition, stirring was continued for 30 minutes, and the temperature was slowly raised to 5°C. Stir at this temperature for 3 hours until the starting material disappears by TLC. The reaction was quenched by adding saturated sodium bisulfite (3.3%, 83 g, 26 mmol) until the starch potassium iodide was free of peroxide. Water (2 L) was a...

Embodiment 2

[0165] Embodiment 2: the synthesis of compound 2.5

[0166]

[0167] Step 1: Synthesis of Compound 2.1

[0168] Compound 1.7 (10g, 24mmol) and 4-dimethylaminopyridine (DMAP) (300mg, 2.4mmol) were dissolved in a mixed solution of acetic anhydride (50mL) and toluene (100mL), and the reaction system was reacted at 110°C for 2 Cool to room temperature one day later, remove the solvent by rotary evaporation under reduced pressure, dissolve the residue in ethyl acetate (200mL), wash the organic phase with cold water (3×50mL) and saturated brine (100mL), separate the organic phase and wash with anhydrous sodium sulfate After drying and concentration, the residue was purified by Flash column chromatography (ethyl acetate / petroleum ether=0-50%) to obtain compound 2.1 (10.4 g, yield: 86%) as a white solid.

[0169] m / z:[M-H] – 503

[0170] Step 2: Synthesis of compound 2.2

[0171] Under ice-bath conditions, dissolve compound 2.1 (1.0 g, 2.0 mmol) in dry tetrahydrofuran (30 mL), ...

Embodiment 3

[0182] Embodiment 3: the synthesis of compound 3.2

[0183]

[0184] Step 1: Synthesis of Compound 3.1

[0185] Under ice-bath conditions, compound 2.1 (3.65g, 7.24mmol) was added to trifluoroacetic acid (6.6mL) and trifluoroacetic anhydride (11.4g, 54.3mmol), stirred until dissolved, and sodium nitrite (1.5 g, 21.7mmol), the addition was completed, and the reaction system was stirred under ice bath for 1 hour, and then stirred at 40°C for 2 hours. The reaction system was neutralized with saturated aqueous sodium bicarbonate solution, then extracted with ethyl acetate (3×50 mL), the organic phases were combined, washed with saturated brine, the organic phase was separated and dried with anhydrous sodium sulfate, concentrated, and the residue After purification by Flash column chromatography (ethyl acetate / petroleum ether=0-20%), compound 3.1 (2.4 g, yield: 70%) was obtained as a pale yellow oil.

[0186] 1 H NMR (400MHz, CDCl 3 ):δ5.11(s,1H),4.54-4.62(m,1H),2.22-2.38(m,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a preparation method and application of a sulfonylurea compound and a composition containing the same component as FXR and / or TGR5 agonist, the FXR and / or TGR5 agonist is a compound shown as a formula (I), or a pharmaceutically acceptable salt, a solvate, a prodrug, an isomer and a stable isotope derivative thereof. The compounds can be used for treatment of FXR and / or TGR5 mediated diseases including primary biliary cirrhosis, nonalcoholic fatty liver, portal hypertension, bile acid diarrhea and cholestasis, type II diabetes and obesity and other field.

Description

technical field [0001] The invention relates to a sulfonylurea compound and its isomer, prodrug or pharmaceutically acceptable salt, stable isotope derivative, its pharmaceutical composition, preparation method and application containing the same component composition. Background technique [0002] The farnesoid X receptor (FXR) is a member of the nuclear hormone receptor superfamily and belongs to one of the transcription factors activated by ligands. This family includes steroid receptors, retinol receptors, and thyroid hormone receptors . FXR is widely present in the liver, intestines, kidneys, adrenal glands, and other tissues where bile acids are present. Cholic acid or its taurine or glycine amide conjugates are known endogenous ligands of FXR, including chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), lithocholic acid (LCA), they can Binds to and activates FXR receptors at physiological concentrations. FXR plays an important regulatory role in bile balance, gl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07J9/00C07J43/00C07J17/00C07J33/00A61K31/64A61K45/06A61P1/16A61P3/06A61P9/10A61P3/10A61P3/04A61P29/00
CPCC07J9/00A61K31/64A61K45/06C07J17/00C07J33/00C07J43/00
Inventor 利群高大新刘胜洋
Owner SHANGHAI DE NOVO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap